Toray Of Japan Accelerates Anti-Itching Agent Clinical Trails In Europe And U.S.
This article was originally published in PharmAsia News
Executive Summary
Currently under approval review in Japan, Toray has sped up the clinic trials overseas for anti-itching agent TRK-820, jointly developed by Toray, Japan Tobacco, Torii Pharma and Maruo Co. In Europe, TRK-820 injection has entered a Phase III trial, and a Phase III trial for TRK-820 oral dose has begun in the U.S. TRK-820 is an opioid k receptor agonist for treating uremic pruritis in hemodialysis patients. Toray hopes to get TRK-820 oral dose approved in Japan within this year. The company also announced that urinary incontinence drug TRK-130 has entered Phase II trials in Japan. (Click here for more - Japanese language